treatment went smoothly participant second injection declined details patient confidentiality team plans treat total people receive injections primarily safety trial participants monitored months determine injections causing adverse effects lu team watch time benefiting treatment oncologists excited crispr entry cancer scene technology able incredible says naiyer rizvi columbia university medical center new york city antonio russo palermo university italy notes antibodies neutralize pd-1 successfully lung cancer check boding crispr enabled attack protein exciting strategy says rationale strong rizvi questions particular trial succeed process extracting genetically modifying multiplying cells huge undertaking not scalable says shows large gain efficacy hard justify moving forward